Phase 2Completed
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 338 enrolled
- Conditions
- Obesity; Overweight
- Interventions
- LY3437943; Placebo
- Ages
- adults, older adults
- Registry
- NCT04881760
Full record on ClinicalTrials.gov
From the registry
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Primary outcomes
- Mean Percent Change From Baseline in Body Weight
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered
Papers citing this trial
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Diabetes, obesity & metabolism
- Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity
Advances in therapy
- Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
Obesity pillars
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Nature medicine
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
The New England journal of medicine